Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Jean-Luc M. Lemercier net worth and biography

Jean-Luc Lemercier Biography and Net Worth

VP of Edwards Lifesciences

Jean-Luc Lemercier has been corporate vice president, EMEA (Europe, Middle East and Africa), Canada and Latin America since July 2017. Prior to assuming his current role, Lemercier served as vice president of transcatheter heart valves EMEA since 2008. Under his leadership at Edwards, the company successfully launched the SAPIEN transcatheter heart valve technology and built its leadership position in Europe. Before joining Edwards, Lemercier served various leadership roles with Johnson & Johnson Cordis from 1996-2008, including leader of the structural heart disease group in the United States; vice president of new business development in Europe, vice president of the Cordis cardiology Europe division in Belgium; and general manager of Cordis France. Lemercier has more than 30 years of medical device experience, beginning with Baxter in France, and held several sales and marketing management positions within Baxter Europe and the United States. Lemercier holds a degree as a doctor in pharmacy from the Claude Bernard Lyon 1 University in Lyon, France.

What is Jean-Luc M. Lemercier's net worth?: The estimated net worth of Jean-Luc M. Lemercier is at least $13.01 million as of May 1st, 2024. Mr. Lemercier owns 173,849 shares of Edwards Lifesciences stock worth more than $13,005,644 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Lemercier may own. Learn More about Jean-Luc M. Lemercier's net worth.
How do I contact Jean-Luc M. Lemercier?: The corporate mailing address for Mr. Lemercier and other Edwards Lifesciences executives is ONE EDWARDS WAY, IRVINE CA, 92614. Edwards Lifesciences can also be reached via phone at (949) 250-2500 and via email at [email protected]. Learn More on Jean-Luc M. Lemercier's contact information.
Has Jean-Luc M. Lemercier been buying or selling shares of Edwards Lifesciences?: Jean-Luc M. Lemercier has not been actively trading shares of Edwards Lifesciences during the past quarter. Most recently, Jean-Luc M. Lemercier sold 14,400 shares of the business's stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a transaction totalling $1,212,624.00. Following the completion of the sale, the vice president now directly owns 173,849 shares of the company's stock, valued at $14,639,824.29. Learn More on Jean-Luc M. Lemercier's trading history.
Who are Edwards Lifesciences' active insiders?: Edwards Lifesciences' insider roster includes Donald Bobo, Jr (VP), Daveen Chopra (VP), Kieran Gallahue (Director), Leslie Heisz (Director), Jean-Luc Lemercier (VP), Daniel Lippis (VP), Martha Marsh (Director), Michael Mussallem (CEO), Robert Sellers (VP), Catherine Szyman (VP), Scott Ullem (CFO), Nicholas Valeriani (Director), Huimin Wang (VP), Larry Wood (VP), and Bernard Zovighian (VP). Learn More on Edwards Lifesciences' active insiders.
Are insiders buying or selling shares of Edwards Lifesciences?: In the last year, Edwards Lifesciences insiders bought shares 1 times. They purchased a total of 580 shares worth more than $49,729.20. In the last year, insiders at the medical research company sold shares 34 times. They sold a total of 377,713 shares worth more than $31,439,247.64. The most recent insider tranaction occured on December, 16th when VP Daniel J Lippis sold 2,500 shares worth more than $185,200.00. Insiders at Edwards Lifesciences own 1.3% of the company. Learn More about insider trades at Edwards Lifesciences.
Information on this page was last updated on 12/16/2024.

Jean-Luc M. Lemercier Insider Trading History at Edwards Lifesciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/1/2024	Sell	14,400	$84.21	$1,212,624.00	173,849
4/8/2024	Sell	14,400	$92.32	$1,329,408.00	173,849
3/11/2024	Sell	14,400	$91.68	$1,320,192.00	173,584
5/9/2023	Sell	6,640	$88.68	$588,835.20	172,090
3/8/2023	Sell	6,640	$76.96	$511,014.40	168,875
11/29/2021	Sell	100	$110.58	$11,058.00
4/1/2021	Sell	13,020	$83.66	$1,089,253.20
2/1/2021	Sell	20,523	$83.51	$1,713,875.73	152,241
1/4/2021	Sell	20,523	$91.24	$1,872,518.52	152,241
4/27/2020	Sell	3,470	$223.50	$775,545.00	45,401
2/27/2020	Sell	3,470	$217.53	$754,829.10	45,288
5/6/2019	Sell	4,188	$176.17	$737,799.96	44,598
4/9/2019	Sell	4,186	$188.23	$787,930.78	44,596
5/9/2018	Sell	5,634	$134.91	$760,082.94	38,784
4/11/2018	Sell	5,633	$139.42	$785,352.86
3/7/2018	Sell	5,633	$136.29	$767,721.57	44,298

Jean-Luc M. Lemercier Buying and Selling Activity at Edwards Lifesciences

Edwards Lifesciences Company Overview

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Today's Range

Now: $74.81

$72.97

$75.27

50 Day Range

MA: $70.06

$65.75

$74.81

2 Week Range

Now: $74.81

$58.93

$96.12

Volume

14,033,775 shs

Average Volume

4,725,668 shs

Market Capitalization

$44.12 billion

P/E Ratio

10.80

Dividend Yield

N/A

Beta

1.12